Compugen (CGEN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.49 (+1.22%), Market cap $0.26B, P/E ratio 7.24, 52-week low–high $1.33 ~ $3.10.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck s
Financial statements, price targets, institutional (13F) holdings and related news for Compugen are updated in real time on BlackAll Trade.
Compugen trades at $2.49 (+1.22%). Real-time quotes and charts are available on BlackAll Trade.
Compugen has a market cap of about $0.26B. Its P/E ratio is 7.24.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United